Table of Contents
Most sponsors focus on a vendor’s technical capabilities. In practice, the success of statistical services depends just as much on how prepared the sponsor is before any vendor conversation begins. When expectations are unclear, timelines are optimistic, or internal alignment is missing, even strong statistical vendors struggle to deliver timely results with the quality you expect.
These seventeen readiness questions are based on patterns seen repeatedly in real clinical trial execution. They highlight the sponsor-side gaps that most often lead to delays, rework, budget overruns, and strained vendor relationships. When sponsors can answer these questions clearly, vendors can estimate accurately, plan realistically, and deliver with fewer surprises.
Use this guide as an internal readiness check before issuing an RFP, shortlisting vendors, or engaging any clinical trial biostatistics or statistical programming provider.
What This Guide Covers
This guide outlines the internal questions sponsors should answer before outsourcing biostatistics or statistical programming for clinical trials. It focuses on readiness across:
- protocol and documentation preparedness
- scope and complexity definition
- timeline realism and recruitment assumptions
- data dependencies and cleanliness
- internal decision-making and governance
- operational onboarding and budget alignment
Who This Guide Is For
This guide is for:
- clinical trial sponsors
- biotech and pharmaceutical companies
- clinical operations and biometrics leaders
- teams preparing to outsource biostatistics or statistical programming
When to Use This Guide
Use this checklist:
- before issuing an RFP for biostatistics or statistical programming
- before shortlisting CROs or functional service providers
- when timelines, budgets, or past vendor relationships have broken down
- when internal teams are unsure why prior studies ran into avoidable issues
Sponsor Readiness vs CRO Vendor Capability
Most statistical delays are not caused by poor programming or weak methodology. They are caused by unclear scope, unrealistic timelines, late decisions, incomplete data, or misaligned internal teams. These are sponsor-side issues. Addressing them early changes the entire dynamic of the vendor relationship.
How to Use the 17 Questions
These questions are not meant to be answered quickly or individually. They work best when reviewed collaboratively across clinical, biometrics, data management, and leadership teams. Disagreements during this exercise are useful. They reveal gaps that would otherwise surface later, when timelines are compressed and options are limited.
If you cannot answer a question confidently, that is a signal to pause and resolve the issue internally before engaging vendors.
Key Takeaways
- Strong vendor performance depends heavily on sponsor readiness.
- Most statistical delays originate from scope gaps, timeline optimism, or data dependencies.
- Overly optimistic recruitment forecasts are a leading cause of downstream timeline failure.
- Clear ownership, decision authority, and governance prevent friction.
- Prepared sponsors receive better proposals, better execution, and more predictable outcomes.
FOUNDATION: What You Need Before Any Statistical CRO Vendor Conversation
1. Do we have a protocol or synopsis that is detailed enough for a biostatistics vendor to estimate accurately?
A partial protocol is sufficient for a vendor to structure and estimate workload accurately. It defines the key statistical decisions that drive complexity and cost. What matters most is clarity around endpoints, populations, and analytical approach.
Why this matters
The protocol is the blueprint for the entire study, including a high-level description of the statistical analysis. Without it, vendors do not know your endpoints, methods, models, populations, visit windows, or missing data approach. These are not minor details. They define hundreds of hours of work. A clear protocol or synopsis helps vendors price accurately, plan resources, and avoid misunderstandings. It also signals organizational readiness.
If you skip this
Vendors will protect themselves by inflating estimates to cover unknown work, or they will underbid and later surprise you with change orders and delays. You will waste weeks answering basic questions that the protocol should have answered.
Checklist
□ Endpoints defined
□ Estimands drafted
□ Populations defined
□ Missing data strategy drafted
□ Visit windows defined
□ Sensitivity analyses listed
□ Multiplicity approach drafted
2. Are we clear on what type of biostatistics vendor we actually need for this trial?
Different vendors offer different levels of thinking, support, and capability. You must choose whether you need strategic guidance or pure execution.
Why this matters
The vendor type you choose determines cost, staffing levels, and overall performance. If your trial needs strategic biostatistical leadership and you hire a coding-focused vendor, you will struggle with every decision. If your trial only needs programming support and you hire a high-touch biostatistics team, you will overspend. Choosing the correct model ensures alignment across expectations, budget, and expertise.
If you skip this
You may select a vendor who is unprepared to lead or overqualified to simply execute. This mismatch causes delays, budget inflation, and frustration on both sides. Leadership will question why the trial is off track when the real issue was hiring the wrong type of vendor.
Checklist
□ Programmers only
□ Programmers plus statisticians
□ Strategic biostatistics partner
Select one. If you cannot select one, you are not as ready to evaluate vendors as you need to be.
3. Are we prepared to provide all required documentation a biostatistics vendor will need to scope and start work?
Vendors need clear documents to estimate properly and begin work smoothly.
Why this matters
Documentation is the foundation for estimation, planning, and risk assessment. If you cannot provide these materials, the vendor cannot price the work accurately or begin promptly. Having these documents ready demonstrates preparation and operational maturity.
If you skip this
Proposals will be inflated, incomplete, or based on inaccurate assumptions. Onboarding will be slow. You will scramble to collect files while the vendor waits idle. Budget surprises will appear once the vendor sees the real scope. The project will feel unorganized before it even starts.
Checklist
□ Protocol or synopsis
□ Schedule of events
□ Correspondence with regulatory authorities
□ Prior analyses or CSR
□ Relevant publications
□ Guidance documents
□ KOL input
“Most statistical delays are not caused by poor programming or weak methodology. They are caused by unclear scope, unrealistic timelines, late decisions, incomplete data, or misaligned internal teams. These are sponsor-side issues. Addressing them early changes the entire dynamic of the vendor relationship.”
SCOPE DEFINITION: What You're Actually Asking Statistical CRO Vendors to Do
4. Have we clearly defined what work the biostatistics vendor is responsible for?
A vendor cannot build accurate proposals if you are not clear about what you want them to handle. Scope defines responsibilities, workload, seniority required, and timing of deliverables.
Why this matters
Scope is the foundation for cost, staffing, planning, and accountability. If your team is unclear about what the vendor will own, it becomes impossible to compare proposals or manage expectations. This leads to disagreements during the project because internal teams assume different things. A well-defined scope protects your budget, prevents rework, and gives the vendor a fair chance to succeed.
If you skip this
You will receive proposals that look unrelated because each vendor is guessing the workload. Prices will vary widely, and leadership will question why estimates differ so much. During the trial, the vendor will say an item was out of scope, and they will not be wrong. You may approve last-minute budget increases or argue over responsibilities. Trust erodes because expectations were never aligned.
Checklist
□ Statistical leadership needed
□ SAP writing or review only
□ Programming only
□ TFL count estimated
□ CDISC needs defined
□ Submission requirements defined
□ Data review or transfer frequency known
□ Interim analysis needs identified
□ ISS or ISE likely or not likely
□ Contingency for last-minute unplanned analyses
5. Do we truly understand how complex our statistical analysis will be?
Many studies look simple on the surface but require substantial statistical work once you examine endpoints, data structure, and protocol realities.
Why this matters
Complexity determines which vendors are qualified and how they price their work. Time-to-event models, repeated measures, composite endpoints, and heavy missing data require senior statisticians and longer timelines. A survival analysis with competing risks can require several times the programming effort of descriptive summaries. If you underestimate complexity, you may choose the wrong vendor or receive proposals far outside expectations.
If you skip this
You risk hiring a vendor who appears affordable but lacks the capabilities required for your trial. They may become overwhelmed or escalate staffing needs mid-study, causing delays and budget inflation. In the worst case, you may need to switch vendors, which is painful, time-consuming, and difficult to justify internally.
Checklist
□ Time-to-event endpoints
□ Repeated measures
□ Multiple or composite endpoints
□ Heavy missing data
□ Country or site-level effects
□ Protocol deviations impacting analysis
□ Adaptive design features
□ Blinded or unblinded safety reviews
6. Do we have enough internal statistical expertise to evaluate and manage a vendor?
Your team needs enough statistical knowledge to assess vendor proposals, validate their approach, and catch problems early.
Why this matters
You cannot evaluate a vendor’s quality if you cannot assess their statistical thinking. Many sponsors hire vendors to fill expertise gaps, but someone internally must still understand whether proposed methods are appropriate, whether timelines are realistic, and whether deliverables meet regulatory expectations. Without this baseline, vendor selection risks being driven by price or presentation rather than merit.
If you skip this
You may hire a vendor proposing inappropriate methods that go unnoticed. You will struggle to judge whether delays are justified or avoidable. Regulatory questions may expose weaknesses late, when fixing them is costly. In the worst case, you become fully dependent on the vendor for decisions that should have internal oversight.
Checklist
□ Internal statistician assigned
□ Ability to assess proposed methods
□ Ability to assess sample size calculations
□ Understanding of regulatory expectations
□ Ability to review SAP content
□ Backup statistical reviewer identified
□ Clear criteria for seeking additional expertise
□ Experience with similar trial designs
7. How much unplanned or exploratory statistical work are we likely to request?
Most sponsors underestimate the volume of ad-hoc work they will ask the vendor to perform. These requests drive cost and timeline variability.
Why this matters
Unplanned work is one of the leading causes of budget overruns and delayed outputs. Leadership requests exploratory analyses. Medical writing asks for additional tables. Protocol amendments require re-runs. All of this consumes time and senior attention. Understanding your organization’s habits allows you to plan realistically.
If you skip this
You will exceed your budget because these tasks were not priced. The vendor may become overstretched and less responsive. Repeated re-runs increase the risk of errors. Your team may perceive the vendor as slow, even though internal requests caused the workload spike.
Checklist
□ Safety plots likely
□ Subgroup analyses likely
□ Leadership often requests ad-hoc analyses
□ Amendments expected
□ Medical writing needs extra outputs
□ Outlier or sensitivity runs likely
□ Data extracts after query bursts likely
8. Do we have a realistic budget range for biostatistics and statistical programming?
Even a rough range provides essential guardrails.
Why this matters
Budget signals service level, staffing expectations, and feasibility.
If you skip this
Time is wasted on misaligned vendors. Proposals may be rejected outright.
Checklist
□ Lean or premium expectations known
□ Senior statistician needs understood
□ Timeline urgency understood
□ CDISC and submission needs defined
□ Ad-hoc workload expectations defined
□ Pricing model preference known
□ DMC or interim support needs defined
OPERATIONAL READINESS: Internal Alignment and Dependencies
9. Are our timelines grounded in realistic enrollment and data availability assumptions?
A timeline is not a wish list. Vendors need dates grounded in operational reality, not optimism.
Why this matters
One of the most common causes of unrealistic timelines is an overly optimistic recruitment forecast. When enrollment slips, downstream assumptions collapse. Database locks move, interim analyses shift, SAP finalization drifts, and statistical outputs are compressed into unrealistic windows. Unrealistic timelines force rushed work, higher costs, and quality risk.
If you skip this
Your analysis timeline will be built on dates that collapse as soon as enrollment slows. You may push vendors to meet impossible deadlines, creating errors, rework, and escalating costs. The issue may be misdiagnosed as vendor underperformance when the root cause is unrealistic planning.
Checklist
□ FPI and LPO based on realistic enrollment assumptions
□ First clean data extract timeline validated
□ SAP finalization not dependent on perfect recruitment
□ QC cycles include buffer time
□ Interim looks aligned with enrollment reality
□ Data refresh cadence understood
10. Do we understand all the upstream data sources and dependencies that affect analysis?
Statistics depends entirely on timely, accurate data from multiple parties.
Why this matters
Statistical vendors cannot work faster than the data they receive. Delays from EDC, labs, imaging, or adjudication ripple through the entire analysis timeline. Mapping dependencies helps identify bottlenecks early and prevents finger-pointing.
If you skip this
You may assume the vendor is slow when they are waiting on data. Meetings become tense, timelines slip quietly, and recovery options shrink. This is one of the most common reasons vendor relationships deteriorate.
Checklist
□ EDC timing known
□ Lab data timing known
□ Imaging timing known
□ PK or PD sources known
□ eCOA or PRO timing understood
□ Adjudication timing understood
□ Integration responsibilities documented
11. Are our internal teams aligned on what they expect from the biostatistics vendor?
Clinical, regulatory, data management, and medical writing often expect different deliverables.
Why this matters
Misalignment is a fast path to scope creep and frustration. Without alignment, vendors receive conflicting instructions and leadership lacks a shared definition of success.
If you skip this
Multiple teams may request unplanned work. Change orders appear. Internal arguments grow. The vendor appears disorganized when the real issue is unclear sponsor expectations.
Checklist
□ Clinical expectations defined
□ Data management expectations defined
□ Biometrics alignment secured
□ Medical writing needs listed
□ Regulatory expectations listed
□ Leadership agreement confirmed
12. Do we have realistic expectations about clinical data cleanliness?
Data quality at each extract determines how quickly and reliably analysis can proceed.
Why this matters
Messy data slows analysis and increases rework. Understanding cleanliness requirements allows for smarter trade-offs between speed and rigor.
If you skip this
You may demand polished outputs from unclean data, triggering repeated re-runs, frustration, and timeline drift. Confidence in the process erodes.
Checklist
□ Historic query turnaround known
□ Interim extract cleanliness realistic
□ LPO cleanliness realistic
□ Third-party data reliability understood
□ Amendment impact understood
□ Freeze type defined
EXECUTION: How You’ll Work Together
13. Do we have a clear decision-making hierarchy for statistical issues?
Analysis slows when decisions stall.
Why this matters
Statistical work requires frequent decisions. Without clear authority, progress becomes stop-start and momentum is lost.
If you skip this
Questions linger. Vendors pause work. Internal disagreements grow. Leadership blames execution rather than decision paralysis.
Checklist
□ SAP deviation owner
□ Population definition owner
□ Clinical model validator
□ Disagreement resolver
□ Re-run approval owner
□ Final decision owner
14. Is there a single internal owner responsible for managing the vendor relationship?
Someone must manage the relationship, coordination, and escalation.
Why this matters
Without ownership, direction fragments and issues linger.
If you skip this
Conflicting priorities emerge. Escalations stall. Accountability fades.
Checklist
□ Internal owner assigned
□ Day-to-day coordinator identified
□ Escalation path clear
□ Scope and budget approval owner defined
□ Meeting cadence agreed
15. Are responsibilities between the sponsor and the vendor clearly defined?
Clear responsibility boundaries prevent gaps and duplication.
Why this matters
Statistical work touches many functions. Clear ownership improves efficiency and accountability.
If you skip this
Tasks fall through the cracks. Problems surface late and are expensive to fix.
Checklist
□ Sponsor versus vendor responsibilities documented
□ Protocol-level statistical ownership defined
□ SAP ownership clear
□ TFL shell approval ownership clear
□ CDISC mapping ownership defined
□ External dataset integration ownership defined
□ Regulatory communication ownership defined
16. Are we operationally ready to onboard a biostatistics vendor without delays?
Onboarding delays quietly derail timelines.
Why this matters
Contracts, QA reviews, and system access must be ready to avoid lost momentum.
If you skip this
The vendor waits idle. Temporary workarounds create later issues. The project starts poorly.
Checklist
□ Contracts queued for review
□ QA qualification scheduled
□ Communication tools agreed
17. Do we know how we will measure and evaluate biostatistics vendor performance?
Clear metrics enable fair evaluation.
Why this matters
Defined expectations allow objective performance management and course correction.
If you skip this
Feedback becomes subjective. Trust erodes. Decisions feel arbitrary.
Checklist
□ Timeline expectations defined
□ Quality standards defined
□ Communication expectations defined
□ Issue-handling expectations defined
□ Performance review cadence defined
□ Steering committee identified
□ Budget variance tolerance defined
Final Thoughts
Vendor selection is often treated as a procurement exercise. In reality, it is an operational readiness test. These seventeen questions are not about judging vendors. They are about reducing avoidable risk before the first contract is signed.
Teams that take the time to answer these questions tend to experience fewer surprises, clearer communication, and more stable timelines. They enter vendor discussions with shared expectations and make decisions based on substance rather than urgency.
Preparation does not slow a study down. It removes the hidden friction that causes studies to stall later, when recovery is far more expensive.
Question Checklist
FOUNDATION: What You Need Before Any Statistical CRO Conversation
1. Do we have a protocol or synopsis that is detailed enough for a biostatistics vendor to estimate accurately?
2. Are we clear on what type of biostatistics vendor we actually need for this trial?
3. Are we prepared to provide all required documentation a biostatistics vendor will need to scope and start work?
SCOPE DEFINITION: What We Are Actually Asking the Vendor to Do
4. Have we clearly defined what work the biostatistics vendor is responsible for?
5. Do we truly understand how complex our statistical analysis will be?
6. Do we have enough internal statistical expertise to evaluate and manage a vendor?
7. How much unplanned or exploratory statistical work are we likely to request?
8. Do we have a realistic budget range for biostatistics and statistical programming?
OPERATIONAL READINESS: Timelines, Data, and Internal Alignment
9. Are our timelines grounded in realistic enrollment and data availability assumptions?
10. Do we understand all the upstream data sources and dependencies that affect analysis?
11. Are our internal teams aligned on what they expect from the biostatistics vendor?
12. Do we have realistic expectations about clinical data cleanliness?
EXECUTION: How the Sponsor and Vendor Will Work Together
13. Do we have a clear decision-making hierarchy for statistical issues?
14. Is there a single internal owner responsible for managing the vendor relationship?
15. Are responsibilities between the sponsor and the vendor clearly defined?
16. Are we operationally ready to onboard a biostatistics vendor without delays?
17. Do we know how we will measure and evaluate biostatistics vendor performance?
